The implementation of iPSCs offers a great mean of cell-based therapy capable of bypassing the usual ethical dilemma associated with ESCs. The iPSCs have the ability to differentiate into tissue-specific neurons which leads to long-term restoration of the lesioned tissue (Romanyuk et al., 2015). Moreover, these cells can be obtained in a non-invasive patient-specific manner that makes iPSC an even more approachable attractive candidate for SCI therapy. This cell replacement therapeutic approach has opened a new era in the field of regenerative medicine.
